298 related articles for article (PubMed ID: 32972438)
1. Advances in the assessment of minimal residual disease in mantle cell lymphoma.
Jung D; Jain P; Yao Y; Wang M
J Hematol Oncol; 2020 Sep; 13(1):127. PubMed ID: 32972438
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
3. Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas.
Sørensen CD; Jørgensen JM; Nederby L; Hokland P; Nyvold CG
J Immunol Methods; 2014 Apr; 406():131-6. PubMed ID: 24631717
[TBL] [Abstract][Full Text] [Related]
4. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathogenesis of mantle cell lymphoma.
Jares P; Colomer D; Campo E
J Clin Invest; 2012 Oct; 122(10):3416-23. PubMed ID: 23023712
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma.
Lokvenc M; Kalinova M; Forsterova K; Klener P; Trneny M; Fronkova E; Kodet R
Ann Hematol; 2018 Mar; 97(3):467-474. PubMed ID: 29273915
[TBL] [Abstract][Full Text] [Related]
7. [Pitfalls and update in haematopathology. Case 2. "Early phase" mantle cell lymphoma of the lymph node].
Copie-Bergman C
Ann Pathol; 2012 Oct; 32(5):336-40. PubMed ID: 23141941
[No Abstract] [Full Text] [Related]
8. Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma.
Wu S; Blombery P; Westerman D; Tam CS
Curr Treat Options Oncol; 2023 Aug; 24(8):929-947. PubMed ID: 37249800
[TBL] [Abstract][Full Text] [Related]
9. SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement.
Szostakowska M; Szymczyk M; Badowska K; Tudek B; Fabisiewicz A
Med Oncol; 2018 Mar; 35(4):49. PubMed ID: 29520657
[TBL] [Abstract][Full Text] [Related]
10. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
Pott C; Schrader C; Brüggemann M; Ritgen M; Harder L; Raff T; Tiemann M; Dreger P; Kneba M
Eur J Haematol; 2005 Apr; 74(4):353-8. PubMed ID: 15777349
[TBL] [Abstract][Full Text] [Related]
11. SOX11, CCND1, BCL1/IgH and IgH-VDJ: a battle of minimal residual disease markers in mantle cell lymphoma?
Simonsen AT; Schou M; Sørensen CD; Bentzen HH; Nyvold CG
Leuk Lymphoma; 2015; 56(9):2724-7. PubMed ID: 25629991
[No Abstract] [Full Text] [Related]
12. VH gene repertoire of mantle cell lymphomas.
Varade W; Marin E; Milano M; Insel R; Swerdlow S; Williams M
Ann N Y Acad Sci; 1995 Sep; 764():504-6. PubMed ID: 7486576
[No Abstract] [Full Text] [Related]
13. A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib.
Scapinello G; Riva M; Branca A; Pizzi M; Bonaldi L; Martines A; Manni S; Visentin A; Trentin L; Semenzato G; Gurrieri C; Piazza F
Ann Hematol; 2020 Nov; 99(11):2715-2717. PubMed ID: 32671454
[No Abstract] [Full Text] [Related]
14. Variant t(2;11)(p11;q13) associated with the IgK-CCND1 rearrangement is a recurrent translocation in leukemic small-cell B-non-Hodgkin lymphoma.
Wlodarska I; Meeus P; Stul M; Thienpont L; Wouters E; Marcelis L; Demuynck H; Rummens JL; Madoe V; Hagemeijer A
Leukemia; 2004 Oct; 18(10):1705-10. PubMed ID: 15306823
[TBL] [Abstract][Full Text] [Related]
15. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes.
Nodit L; Bahler DW; Jacobs SA; Locker J; Swerdlow SH
Hum Pathol; 2003 Oct; 34(10):1030-4. PubMed ID: 14608537
[TBL] [Abstract][Full Text] [Related]
16. What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes?
Witzig TE
Hematol Oncol Clin North Am; 2020 Oct; 34(5):825-835. PubMed ID: 32861280
[TBL] [Abstract][Full Text] [Related]
17. Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial.
Genuardi E; Romano G; Beccuti M; Alessandria B; Mannina D; Califano C; Rota Scalabrini D; Cortelazzo S; Ladetto M; Ferrero S; Calogero RA; Cordero F
Br J Haematol; 2021 Jul; 194(2):378-381. PubMed ID: 34002365
[TBL] [Abstract][Full Text] [Related]
18. Analysis of clonal relationship using single-cell polymerase chain reaction in a patient with concomitant mantle cell lymphoma and multiple myeloma.
Yamaguchi M; Ohno T; Miyata E; Toyoda H; Nishii K; Masuya M; Kita K; Shiku H
Int J Hematol; 2001 Apr; 73(3):383-5. PubMed ID: 11345207
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study.
Cheminant M; Derrieux C; Touzart A; Schmit S; Grenier A; Trinquand A; Delfau-Larue MH; Lhermitte L; Thieblemont C; Ribrag V; Cheze S; Sanhes L; Jardin F; Lefrère F; Delarue R; Hoster E; Dreyling M; Asnafi V; Hermine O; Macintyre E
Haematologica; 2016 Mar; 101(3):336-45. PubMed ID: 26703963
[TBL] [Abstract][Full Text] [Related]
20. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
